Jove
Visualize
Contact Us

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

606
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
606
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

655
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
655
Local Anesthetics: Differential Sensitivity of Nerve Fibers01:24

Local Anesthetics: Differential Sensitivity of Nerve Fibers

1.6K
Local anesthetics (LAs) block the sodium channels of nerve trunks, sensory nerve endings, and neuromuscular junctions. Although LAs can block all kinds of nerves, the sensitivity of nerve fibers differs according to nerve types and structures. LAs are known to block myelinated fibers faster than unmyelinated ones. Also, they block pain or sensory neurons at low concentrations without affecting the motor neurons involved in muscle contractions. This helps relieve labor pain without affecting the...
1.6K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

602
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
602
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

717
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
717
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.1K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The psychosocial impact of disability and stigma among persons affected by leprosy and lymphatic filariasis in India.

PLOS mental health·2026
Same author

Increasing Awareness and Early Detection of Common Skin Diseases in Indonesia Through an mHealth App: Protocol for an Awareness and Acceptability Study and Randomized Controlled Trial.

JMIR research protocols·2025
Same author

Risk factors and leprosy incidence among contacts in Bangladesh: A multilevel analysis.

PLoS neglected tropical diseases·2025
Same author

Integrative immune analysis in patients with leprosy reveals host factors associated with mycobacterial control.

EBioMedicine·2025
Same author

Early Detection of Common Skin Diseases, Including Leprosy: Development and Validation of an Awareness Questionnaire.

International journal of public health·2025
Same author

What ails tuberculosis notification from the private sector in urban India: a qualitative study among stakeholders in Bengaluru City, southern India.

Frontiers in public health·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 20, 2026

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
09:44

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

19.9K

Corticosteroids for treating nerve damage in leprosy.

Natasja H J Van Veen1, Peter G Nicholls, W Cairns S Smith

  • 1Department of Public Health, Erasmus Medical Center, PO Box 2040, Rotterdam, Netherlands, 3000 CA.

The Cochrane Database of Systematic Reviews
|May 24, 2016
PubMed
Summary

Corticosteroids do not improve nerve function in leprosy patients compared to placebo. More research is needed to determine optimal treatment regimens for nerve damage and explore new therapies.

More Related Videos

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

2.0K
Author Spotlight: Establishing a Practical and Cost-Effective Protocol for Corneal Sensitivity Testing in Clinical Settings
04:00

Author Spotlight: Establishing a Practical and Cost-Effective Protocol for Corneal Sensitivity Testing in Clinical Settings

Published on: August 2, 2024

3.5K

Related Experiment Videos

Last Updated: Mar 20, 2026

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
09:44

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

19.9K
Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

2.0K
Author Spotlight: Establishing a Practical and Cost-Effective Protocol for Corneal Sensitivity Testing in Clinical Settings
04:00

Author Spotlight: Establishing a Practical and Cost-Effective Protocol for Corneal Sensitivity Testing in Clinical Settings

Published on: August 2, 2024

3.5K

Area of Science:

  • Neurology
  • Infectious Diseases
  • Pharmacology

Background:

  • Leprosy frequently causes nerve damage, leading to impairment and disability.
  • Corticosteroids are a common treatment for nerve damage, but their long-term efficacy remains unclear.
  • This review is an update of previous analyses on corticosteroid effectiveness in leprosy.

Purpose of the Study:

  • To evaluate the effects of corticosteroids on nerve damage in individuals with leprosy.
  • To assess nerve function improvement, pain reduction, and adverse events associated with corticosteroid treatment.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) and quasi-RCTs.
  • Searched multiple databases including Cochrane, MEDLINE, EMBASE, CINAHL Plus, and LILACS.
  • Primary outcome: nerve function improvement at one year; secondary outcomes: pain, daily living limitations, participation, and adverse events.

Main Results:

  • Five RCTs with 576 participants were included, generally at low risk of bias.
  • Two trials showed no significant difference in nerve function improvement between prednisolone and placebo after 12 months.
  • Adverse events were not significantly more frequent with corticosteroids; other trials examined different regimens and found no significant differences in adverse events.

Conclusions:

  • Moderate-quality evidence suggests corticosteroids are not superior to placebo for improving nerve function in leprosy, particularly for longstanding or mild impairment.
  • Further RCTs are required to establish optimal corticosteroid regimens and evaluate new therapies.
  • Future research should also consider non-clinical outcomes like quality of life and costs.